Cardio3 BioSciences Completes Patient Enrolment in First Stage of Pivotal Trial of C-Cure(R) in Heart Failure
- 45 Patients Enrolled in Study Designed to Evaluate the Ability of Cardiopoietic Cells to Restore Cardiac Function
Cardio3 BioSciences, a leading Belgian biotechnology company specialising
in cell-based therapies for the treatment of cardiovascular diseases,
announced today that it has completed, two months ahead of schedule,
enrolment in the first stage of its pivotal Phase II/III trial of C-Cure, a
unique stem cell therapy for heart failure. Forty-five patients have now
enrolled in the study which is being conducted at centres in
C-Cure is produced by taking a patient's own bone marrow cells and,
through a proprietary process, differentiating them into cardiopoietic cells
that can regenerate damaged heart muscle. The cardiopoietic cells are
injected into the heart of a patient with heart failure where they are
designed to behave identically to those cells lost in heart failure without
carrying the risk of rejection, something that has not been achieved with
previous cell therapies for this indication. C-Cure is the outcome of
multiple years of research conducted at Mayo Clinic (
Safety data from this stage of the trial is expected to be available in
Heart failure is a serious and common condition in which the heart cannot
pump enough blood through the body, leaving the patient debilitated and
unable to conduct a normal life. It can result from heart attacks or a number
of other causes. Patients suffering from the condition can experience
shortness of breath and extreme exhaustion. It affects 20 million patients in
About Cardio3 BioSciences
Cardio3 BioSciences is a leading Belgian biotechnology company specialising in stem cell-based therapies for the treatment of cardiovascular disease. The Company's lead product, C-Cure, is a highly innovative approach to the treatment of heart failure, one of the world's most pressing unmet medical needs. Based on a strategy developed by Cardio3 BioSciences' founders and leveraging technology from Mayo Clinic, C-Cure allows the differentiation of a patient's own cells into cardiopoeitic cells which grow into new heart cells and repair heart muscle.
The Cardio3 BioSciences team has extensive experience in developing and commercialising new pharmaceutical products and medical technologies and the Company's strategy is to drive the clinical development of C-Cure and to market the product itself in major territories.
Cardio3 BioSciences was founded in
Mayo Clinic has a financial interest in technology related to this research and may stand to gain from the successful outcome of the research. Mayo Clinic holds equity in Cardio3 BioSciences as a result of intellectual property licensed to the company.
For more information contact: Cardio3 BioSciences: Dr Christian Homsy, CEO, Tel: +32-10-39-41-00, firstname.lastname@example.org . Mayra Beydoun, Brand & Communication Manager, Tel : +32-10-39-41-00, email@example.com . http://www.c3bs.com Citigate Dewe Rogerson: Chris Gardner/Nina Enegren, Tel : +44(0)207-638-9571, firstname.lastname@example.org .
SOURCE Cardio3 BioSciences